公开资料显示，恩格列净是由德国勃林格殷格翰研发、与礼来联合推广的SGLT2抑制剂类药物。作为全 球三大SGLT2抑制剂之一，恩格列净凭借其独特的降糖机制和心血管、肾脏保护作用，成为糖尿病治疗 领域的明星药物。近年来，在中国的三大终端和六大市场中，恩格列净片的销售规模迅速扩大，尤其在 2024年达到了10亿元的里程碑，并在2025年第一季度实现了接近20%的同比增长。 消息面上，1月5日，据中国国家药品审评中心(CDE)官网最新公示，石药集团全资附属公司石药集团欧 意药业有限公司按化药注册分类4类申报的恩格列净片上市申请获受理。公开资料显示，恩格列净片作 为钠葡萄糖共转运体2(SGLT-2)抑制剂，主要用于治疗2型糖尿病、心力衰竭和慢性肾脏病。 石药集团(01093)涨超3%，截至发稿，涨3.39%，报9.15港元，成交额2.97亿港元。 ...

Core Viewpoint - The article highlights the significant benefits of Semaglutide for patients with type 2 diabetes and peripheral artery disease (PAD), emphasizing its ability to improve walking ability and quality of life, independent of traditional metabolic improvements [8][19][20]. Group 1: Research Findings - Semaglutide shows a notable improvement in maximum walking distance (MWD) and pain-free walking distance (PFWD) for patients with symptomatic PAD [22]. - The STRIDE trial included 792 patients with symptomatic PAD, demonstrating that Semaglutide's efficacy is consistent across various patient characteristics, including diabetes duration, BMI, and blood sugar control [9][10][15]. - The study revealed that the improvement in walking ability is not significantly correlated with weight loss or blood sugar control, suggesting a novel mechanism of action for Semaglutide [17][18]. Group 2: Patient Characteristics and Efficacy - The efficacy of Semaglutide is consistent regardless of diabetes duration (less than 10 years vs. 10 years or more), BMI (less than 30 vs. 30 or more), and blood sugar levels (HbA1c less than 7% vs. 7% or more) [12][13][14]. - Patients using other glucose-lowering medications, such as SGLT2 inhibitors or insulin, also experienced significant improvements in walking ability [14] . Group 3: Safety and Clinical Implications - The safety profile of Semaglutide is comparable to that of the placebo group, with a balanced distribution of gastrointestinal side effects across subgroups [17][18]. - The findings suggest that Semaglutide could be a comprehensive treatment option for PAD in type 2 diabetes patients, enhancing lower limb circulation and functional capacity [20][21].